New drug shows promise for Hard-to-Treat prostate cancer
NCT ID NCT04288687
First seen Mar 12, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This study tested a drug called niraparib in 11 men with advanced prostate cancer that was no longer responding to hormone therapy. All participants had previously received platinum chemotherapy and had specific DNA repair defects. The goal was to see if niraparib could slow cancer growth and lower PSA levels. Results suggest it may help control the disease, but more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.